Tuberculosis Clinical Trial
Official title:
A Phase 1, Randomized, Controlled, Double-blind, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of AERAS-422 in Healthy Adults
Verified date | August 2012 |
Source | Aeras |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to evaluate the safety and immunogenicity of AERAS-422 in healthy, BCG-naïve adults.
Status | Completed |
Enrollment | 24 |
Est. completion date | May 2012 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: -=18 years and =45 years of age on randomization day - Has general good health, confirmed by medical history and physical examination - Has a screening body mass index (BMI) =19 and <33 - Females physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use acceptable method of avoiding pregnancy from 28 days prior to randomization through the end of the study. - Acceptable methods of avoiding pregnancy -Females physically capable of pregnancy must have: - Negative urine pregnancy test within 21 days prior to randomization AND within 24 hours prior to Study Day 0 vaccination - Ability to complete all protocol study visits and be reachable by telephone - Provided written informed consent prior to screening evaluations - Completed simultaneous enrollment in the Aeras Vaccine Registry protocol Exclusion Criteria: - Acute illness on randomization day - Oral temperature >=37.5 degrees C on randomization day - Abnormal laboratory values from blood collected within 21 days prior to randomization as follows: - Positive test for hepatitis B core antibody or hepatitis C antibody - Positive test for HIV - Positive urine test for opiates, cocaine, or amphetamines - Positive QuantiFERON®-TB Gold test - History of treatment for active or latent tuberculosis infection - Other evidence of active or latent tuberculosis, in the opinion of the investigator - Tuberculin skin test (TST) within 90 days prior to randomization - History or evidence of allergic disease or reaction that in the opinion of the investigator is likely to be exacerbated by any component of AERAS-422 or BCG Tice - History or evidence of autoimmune disease, immunosuppression, or immunodeficiency, in the opinion of the investigator - History or evidence of cheloid formation, axillary or cervical lymphadenopathy, or other dermatologic or anatomic findings that, in the opinion of the investigator, may interfere with the assessment of injection site reactions - History or evidence of any other acute or chronic disease or condition that, in the opinion of the investigator, may compromise the safety of the subject or interfere with the evaluation of the vaccine safety or immunogenicity - Medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely the subject will comply with the protocol - Inability to discontinue daily prescription medications (except contraceptives) during the study. - Received immunosuppressive medication within 45 days prior to randomization (inhaled and topical corticosteroids are permitted) - Received investigational drugs or vaccine products within 182 days prior to randomization, or planned participation in any other investigational study during the study - Received investigational Mtb vaccine at any time prior to randomization - Received vaccination or immunotherapy with a BCG product at any time prior to randomization - Received immunoglobulin or blood products within 45 days prior to randomization - Received inactivated influenza vaccine within 14 days prior to randomization or any other standard vaccine within 45 days prior to randomization. - Received systemic antibiotics within 14 days prior to randomization |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | St. Louis University Hospital | St. Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Aeras |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety | Assessment of collected unsolicited and solicited adverse events (including site of injection reaction (pain, erythema, induration, ulceration, drainage, and scarring), regional lymphadenopathy (axillary and cervical), fever, headache, myalgia, arthralgia and fatigue. The adverse event collection timeframe includes all events that occur up to 56 days after study vaccination. Assessment of serious adverse events will be based on events collected throughout the duration of the study. All safety data will be evaluated before moving into the next successive dose level. | Days 0, 3, 7, 14, 28, 56, 84, 112, 140 & 182 | Yes |
Secondary | Immunogenicity | Measurement of immunogenicity based on the percentage of cytokine producing T cells. | Days 0, 14, 28, 56, 84, 112, 140 and 182 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |